Art. -Nr.: HY-N8355

Beauveriolide I

Name: Beauveriolide I
Brand: MedChemExpress
SKU: HY-N8355
Price: 610.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Kundenbewertung

Based on 1 Customer Validation

Beauveriolide I is an ACAT/SOAT inhibitor. Beauveriolide I selectively inhibits macrophage cholesteryl ester synthesis, blocks cholesteryl ester recycling, reduces cholesterol concentration, lipid droplet accumulation, and post-lysosomal cholesterol metabolism, and promotes the degradation of cholesteryl esters preferentially over triglycerides. Beauveriolide I reduces amyloid β peptide secretion. Beauveriolide I exhibits insecticidal and weak antibacterial activities. Beauveriolide I can be used in research on atherosclerosis, Alzheimer's disease, and cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.6%
CAS. Nr.: 154491-55-1
Formel: C₂₇H₄₁N₃O₅
Molecular Weight:487.63

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Beauveriolide I Chemical Structure

CAS. Nr.: 154491-55-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]^[2]

ACAT

SOAT

Alle Acyltransferase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
KB 3-1	IC50	13.3 μM	Cytotoxicity against human endocervical adenocarcinoma KB3.1 cells assessed as IC50 by serial dilution assay in 96-well microtiter plates. Cytotoxicity against human endocervical adenocarcinoma KB3.1 cells assessed as IC50 by serial dilution assay in 96-well microtiter plates.	41424705
A549	IC50	0.9 μM	Cytotoxicity against human lung carcinoma A549 cells assessed as IC50 by serial dilution assay in 96-well microtiter plates. Cytotoxicity against human lung carcinoma A549 cells assessed as IC50 by serial dilution assay in 96-well microtiter plates.	41424705
A-431	IC50	1.2 μM	Cytotoxicity against human epidermoid carcinoma A431 cells assessed as IC50 by serial dilution assay in 96-well microtiter plates. Cytotoxicity against human epidermoid carcinoma A431 cells assessed as IC50 by serial dilution assay in 96-well microtiter plates.	41424705
PC-3	IC50	3.5 μM	Cytotoxicity against human prostate carcinoma PC-3 cells assessed as IC50 by serial dilution assay in 96-well microtiter plates. Cytotoxicity against human prostate carcinoma PC-3 cells assessed as IC50 by serial dilution assay in 96-well microtiter plates.	41424705

In Vitro

Beauveriolide I inhibits cytosolic lipid droplet accumulation in mouse peritoneal macrophages, with no cytotoxicity at concentrations up to 20 µM^[1].
Beauveriolide I selectively inhibits [¹⁴C]CE synthesis in mouse peritoneal macrophages with an IC₅₀ of 0.78 µM, while not inhibiting [¹⁴C]TG synthesis^[1].
Beauveriolide I inhibits the metabolism of lysosomal [¹⁴C]cholesterol to [¹⁴C]CE in mouse peritoneal macrophages, with an IC₅₀ of 0.37 µM^[1].
Beauveriolide I inhibits ACAT activity in mouse macrophage microsomes (IC₅₀ 6.0 µM), mouse liver microsomes (IC₅₀ 1.5 µM), and human Caco-2 microsomes (IC₅₀ 2.5 µM)^[1].
Beauveriolide I selectively enhances [¹⁴C]CE degradation in CHO-K1 cells with an EC₅₀ of 0.02 µM; its EC₅₀ for [¹⁴C]TG degradation is >2.0 µM^[2].
Beauveriolide I inhibits cell-based [¹⁴C]CE synthesis in CHO-K1 cells with an IC₅₀ of 0.01 µM; its IC₅₀ for [¹⁴C]TG synthesis is >2.0 µM^[2].
Beauveriolide I inhibits SOAT activity in CHO-K1 microsomes with an IC₅₀ of 0.05 µM^[2].
Beauveriolide I (compound 1) (0.08 μM; 96 h) reduces cholesteryl ester levels in 7WD10 CHO cells with an IC₅₀ of 0.08 μM and decreases lipid droplet accumulation^[5].
Beauveriolide I (1 μM; 4 days) reduces Aβ40 and Aβ42 secretion in 7WD10 CHO cells, producing approximately 25% and approximately 10% reductions, respectively^[5].
Beauveriolide I showed weak antibacterial activity against Staphylococcus aureus and Bacillus subtilis, with an MIC of 66.6 µg/mL^[4].
Beauveriolide I exhibits cytotoxicity against KB3.1, A549, A431, and PC-3 cancer cell lines, while showing no significant toxicity to mouse fibroblasts^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA Assay^[5]

Cell Line:

stable transgenic CHO cell line 7WD10 expressing human APP751
Concentration:

1 μM (up to 4 days incubation); 1 and 5 μM (96 h incubation)
Incubation Time:

up to 4 days (Aβ40/Aβ42 secretion); 96 h (concentration-effect study)
Result:

Decreased Aβ40 and Aβ42 secretion at 1 μM for up to four days; after four days, reduced Aβ40 by ~25% and Aβ42 by ~10% relative to vehicle control cells.
Reached maximum effect after one to two days.
Reduced Aβ_total (Aβ40 + Aβ42) after 96 h at 1 and 5 μM.

In Vivo

Beauveriolide I (1-10 μg/body; injection) produces ca. 20% insecticidal activity against Spodoptera litura larvae^[3].
Beauveriolide I (10 μg/body; injection) produces 40% insecticidal activity against female Callosobruchus chinensis and no damage to males^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

larva^[3]
Dosage:

10 μg/body (DMSO solution, 0.4 μl); 1 μg/body (DMSO solution, 0.4 μl)
Administration:

injection
Result:

Resulted in 12 survival, 0 agony, and 3 death among 15 larvae at 10 μg/body.
Resulted in 14 survival, 0 agony, and 1 death among 15 larvae at 1 μg/body.
Exhibited ca. 20% insecticidal activity against Spodoptera litura larvae at 10 μg/body.

Animal Model:

adult male and female^[3]
Dosage:

10 μg/body (MeOH-CHCl3 1/1 solution, 0.5 μl)
Administration:

injection
Result:

Resulted in 9 survival, 1 agony, and 0 death among 10 male adults at 10 μg/body.
Resulted in 5 survival, 1 agony, and 4 death among 10 female adults at 10 μg/body.
Showed 40% insecticidal activity against females and no damage to males at 10 μg/body.

Related Protocols :

Chemical Information

CAS. Nr. 154491-55-1
Appearance Solid
Molecular Weight 487.63
Formel C₂₇H₄₁N₃O₅
Color White to light yellow
SMILES

O=C(N[C@H](C(N[C@@H]1CC(C)C)=O)C)[C@@H](NC(C[C@@](OC1=O)([H])[C@@H](C)CCCC)=O)CC2=CC=CC=C2
Structure Classification
- Alkaloids
- Other Alkaloids
Initial Source
- Microorganisms
Beauveria sp.
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (300 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Namatame I, et al. Antiatherogenic activity of fungal beauveriolides, inhibitors of lipid droplet accumulation in macrophages. Proceedings of the National Academy of Sciences of the United States of America. 2004 Jan 20;101(3):737-42.

[2]. Nur EAA, et al. Screening for microbial potentiators of neutral lipid degradation in CHO-K1 cells. Drug discoveries & therapeutics. 2022 Dec 26;16(6):273-279.

[3]. Mochizuki K, et al. The Structures of Bioactive Cyclodepsipeptides, Beauveriolides I and II, Metabolites of Entomopathogenic Fungi Beauveria sp. Bull Chem Soc Jpn. 1993 Oct;66(10):3041‑3046.

[4]. Charria Girón E, et al. Chemical clues to infection: A pilot study on the differential secondary metabolite production during the life cycle of selected species. IMA fungus. 2025;16:e172651.

[5]. Witter DP, et al. The natural products beauveriolide I and III: a new class of beta-amyloid-lowering compounds. Chembiochem : a European journal of chemical biology. 2009 May 25;10(8):1344-7.

[6]. Wang X, et al. Genome mining and biosynthesis of the Acyl-CoA:cholesterol acyltransferase inhibitor beauveriolide I and III in Cordyceps militaris. Journal of biotechnology. 2020 Feb 10;309:85-91.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Beauveriolide I

Alle Acyltransferase Isoform-spezifische Produkte anzeigen